Don’t Ignore Your Kidneys: Early Action Can Slow CKD
January 19, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
voreloxin
Class :
N/A
Brand Name :
N/A
Synonyms :
voreloxin
Class :
N/A
To treat refractory or relapsed AML, administer 80–90 mg/m2 intravenously on days 1 and 4 (in combination with cytarabine).
AML newly diagnosed in elderly patients: 72 mg/m2 intravenously on days 1 and 8 twice daily.
Indicated for Platinum resistant Ovarian Cancer
:
Administer 60 to 75mg/m2 intravenously every 4 weeks; administer infusion intravenously over 5 to 10 minutes.
Refer adult dosing
Actions and Spectrum:
Mechanism of Action: voreloxin is a synthetic small-molecule drug that belongs to the class of compounds known as topoisomerase II inhibitors. It is designed to inhibit the activity of topoisomerase II enzymes, specifically topoisomerase II alpha. Topoisomerases are enzymes involved in DNA replication, repair, and transcription by regulating the topology of DNA. By inhibiting topoisomerase II, voreloxin interferes with DNA replication and cell division, ultimately leading to cell death.
Spectrum of Activity: voreloxin has shown activity against various cancer cell lines and preclinical models, including AML and ovarian cancer. It has demonstrated cytotoxic effects by targeting rapidly dividing cancer cells and disrupting their DNA replication processes.
Frequency NOT defined
Neutropenia
Anemia
Vomiting
Loss of appetite
Diarrhea/colitis
Hypocalcemia
Confusion
Mucositis
Fatigue
Nausea
Hypokalemia
Mucosal inflammation
Hypophosphatemia
Dehydration
Black box warning:
None
Contraindications/caution:
Contraindications:
N/A
Caution:
N/A
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
N/A
Pharmacodynamics:
N/A
Pharmacokinetics:
N/A
Administration:
N/A
Patient information leaflet
Generic Name: voreloxin
Why do we use voreloxin?
voreloxin was being studied for its potential therapeutic effects in the treatment of various types of cancer, including:
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
